WTWilliam Nathanial Tjandrawidjaya

William Nathanial Tjandrawidjaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William Nathanial Tjandrawidjaya has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    On paper; in practice: measuring compliance with official pricing policies in a large field study of essential medicines in Indonesia

    by Ayu Rahmawati, H. U. Ramadaniati, Y. Anggriani, W. Nathanial, E. Pisani

    In 2015, Indonesia Ministry of Health (MoH) issued a decree to ensure the affordability of medicines by providing transparent prices which obliged all manufacturers to print a maximum retail price (MRP) on medicine primary packaging. We measure the compliance of manufacturers and retailers with the regulation stated in the decree and estimate the retailers’ profit. Five essential medicines (allopurinol, amlodipine, amoxicillin, cefixime, dexamethasone) were purchased from randomly selected health facilities, retail pharmacies and online outlets in Indonesia. We recorded retailer’s selling price and product’s MRP. We also sourced product’s list price and sales volume from pharmaceutical market data. We conducted an MRP policy implementation analysis by evaluating three indicators (retail price transparency, permitted MRP and permitted sales price). We also estimated the retailers’ profit by taking into account the profit margin and sales volume. Of 1249 sampled medicines, nearly all samples (99.4%) had visible MRP on their packaging indicating high transparency compliance. For unbranded generics, none complied with permitted MRP with a median ratio of printed MRP to permitted MRP being 3.5 (IQR 2.6–7.9), whilst higher compliance (11.2%) was observed for branded generics (IQR 1.1–1.7, median 1.1). 33% of the samples were sold above the printed MRP with the lowest compliance to actual selling price being documented in hospitals. Branded generics accounted for 79% of the product value across the study medicines and generated more profits than the unbranded versions. The transparency implementation through printed MRP and the compliance with permitted sales price regulation contribute to retailer accountability. Rules restricting permitted MRPs for unbranded generics, irrational since their inception, while they never set any limits at all on the price of branded medicines. This showed not enough evidence that the policy contributed to its objective of ensuring affordability.


  • Open Access

    Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia

    by Vinky Maria, William Nathanial Tjandrawidjaya, Ayu Rahmawati, Prih Sarnianto, Yusi Anggriani, Elizabeth Pisani

    Background: Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Industry groups warn unsustainably low prices threaten quality, while the government says medicines remain overpriced. We investigate the relationship between the price and quality of essential medicines and the affordability of medicines paid for out of pocket.Methods: We bought over 1000 samples of five common prescription medicines—allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone—online and from randomly selected pharmacies and health facilities in four regions across Indonesia. We recorded the price paid and tested samples for quality using high-performance liquid chromatography. We compared prices with the median and lowest prices for each medicine, tested for correlation between quality and price, and calculated affordability compared with the district minimum wage.Results: Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.3 to 18.6 times the median price for the medicine and dose (IQR: 0.9–5.0, median 1.4). Unbranded generics traded in a narrower range (range 0.1–2.6; IQR 0.6–1.0, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th percentile of available prices cost a maximum of 0.7% of 1 day’s wage for a course.Conclusion: In every study district, we found that Indonesian patients working at the minimum wage could access affordable, quality-assured versions of all studied essential medicines. More expensive brands were also widely available, but there was no relationship between price and quality.


  • Open Access

    Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia

    by Vinky Maria, William Nathanial Tjandrawijaya, Ayu Rahmawati, Yusi Anggriani, Prih Sarnianto, Elizabeth Pisani

    Background Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Public narratives have questioned the quality of low-cost medicines, including those provided free to insured patients. We investigate the relationship between medicine price and quality, and the affordability of medicines paid for out of pocket. Methods We bought over 1,000 samples of five common prescription medicines -- allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone -- online and from randomly-selected pharmacies and health facilities in four regions across Indonesia, recording price paid, and testing samples for quality using high performance liquid chromatography. We compared prices with the median price for the same medicine; tested for correlation between quality and price, and calculated affordability compared with the district minimum wage. Results Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.1 to 23.1 times the median price for the medicine and dose (interquartile range: 0.9 – 4.8, median 1.4). Unbranded generics traded in a narrower range (range: 0.1 – 3.2; IQR: 0.5 - 1, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th centile of available prices cost a maximum of 0.7% of one day’s wage for a course. Conclusion Though medicine price vary very widely in Indonesia, we found that affordable varieties of common prescription medicines were widely available across the country, and these medicines were no more likely to fail quality testing than those costing several times as much.


  • Open Access

    A randomised survey of the quality of antibiotics and other essential medicines in Indonesia, with volume-adjusted estimates of the prevalence of substandard medicines

    by Elizabeth Pisani, Ayu Rahmawati, Esti Mulatsari, Mawaddati Rahmi, William Nathanial, Yusi Anggriani, the STARmeds Study Group.

    Introduction Most substandard and falsified medicines are at best not optimally effective, and at worst fatal. While the World Health Organisation and others warn they are a major threat to public health in low and middle income countries, little is known about their true prevalence. Authors of meta-analyses universally warn that survey data are not generalisable, because of unrepresentative study designs and variations in medicines included; tests performed; reference standards and pharmacopeia used; and definitions used when translating multiple quality parameters into a single pass/fail measure. We hypothesised that weighting for sales volume of different products and brands would increase accuracy of estimates of medicine quality. Methods and Findings We collected samples of allopurinol, amlodipine, cefixime and dexamethasone, as well as amoxicillin in 2 formulations in seven districts across Indonesia, the world’s fourth most populous country. Outlets, including retail pharmacies, over the counter medicine shops, public and private hospitals, primary health centres, doctors and nurses were randomised. We also sampled from the internet. Retail samples were collected by mystery shoppers, other samples overtly. We tested 1274 samples for identity and assay, and all relevant samples for dissolution and uniformity of content, using USP reference standards and monographs. Samples that failed any laboratory test were considered out of specification. We calculated prevalence per product and brand, and weighted the results by the sales volume of each product, using sales data from IQVIA and the national public procurement system. The weighted prevalence of out-of-specification products was 4.9%, 40.3% lower than the raw estimate (8.2%). Antibiotics were more likely to be substandard (weighted prevalence 6.8 vs 3.1; raw prevalence 13.6 vs 4.9, pConclusions Where data are available, weighting survey results by sales volume is a cost-effective way of improving the accuracy of estimates of out-of-specification medicines measured in field surveys.